首页> 外文会议>Symposium and Annual Meeting of the International Society for Ceramics in Medicine >Bone Morphogenetic Protein-2 Incorporated Beta-Tricalcium Phosphate Enhanced Bone Regeneration of Critical-Sized Bone Defects in Rats
【24h】

Bone Morphogenetic Protein-2 Incorporated Beta-Tricalcium Phosphate Enhanced Bone Regeneration of Critical-Sized Bone Defects in Rats

机译:骨形态发生蛋白-2掺入β-磷酸钙,提高大鼠临界骨缺损的骨质再生

获取原文

摘要

Although preclinical and clinical studies have shown the benefits of bone morphogenetic protein-2 (BMP2) in bone regeneration, there are increasing concerns about its side effects. These are mainly due to the high dosage of BMP2 which is necessary to obtain the desired clinical results. Previously our group has developed a novel controlled-release delivery system; the biomimetic calcium phosphate coating incorporated with BMP2. It can be used at much lower concentrations of BMP2 than those used in the commercially available product and still produce similar biological effects. In this study, we made a primarily biological evaluation of BMP2 incorporated beta-tricalcium phosphate (β-TCP) for bone regeneration in critical-sized bone defects. Critical-sized calvarial defects were created in rats. They were divided into four groups as follows: (1) empty defects (control), (2) defects filled with β-TCP, (3) defects filled with BMP2 incorporated β-TCP, (4) defects filled with autologous bone. Eight weeks after the operation, the efficiency of the materials was evaluated using histology and histomorphometry. Moreover, the safety of the materials was evaluated using routine blood examination, blood biochemistry examination and histopathological examination of viscera. BMP2 incorporated β-TCP demonstrated an efficiency of bone regeneration that was comparable with autologous bone, with the highest levels of new bone formation (38.3±8.4 mm~3 versus 30.1±9.9 mm~3, p < 0.05). All clinical lab index of blood in these four groups were within the normal range. Moreover, no change related to the treatment was noted in the histopathological examination of viscera. The results from the present study demonstrated that BMP2 incorporated β-TCP could be a promising substitute for autologous bone used for bone regeneration. Future clinical trials and preclinical trials with large animal models are necessary to investigate the safety and efficacy of BMP2 incorporated β-TCP.
机译:虽然临床前和临床研究表明骨质发生蛋白-2(BMP2)在骨再生中的益处,但对其副作用越来越担心。这些主要是由于BMP2的高剂量,这是获得所需的临床结果所必需的。此前,本集团开发了一种新颖的控释交付系统;含有BMP2的仿生磷酸钙涂料。它可以以低于市售产品中使用的BMP2的低浓度使用,并且仍然产生类似的生物学效应。在这项研究中,我们主要在临界大小骨缺损中进行BMP2掺入β-三钙(β-TCP)的BMP2掺入β-β-TCP)。在大鼠中创建了临界大小的颅骨缺陷。它们分为四组,如下:(1)空缺(控制),(2)填充β-TCP的缺陷,(3)填充有BMP2的缺陷掺入β-TCP,(4)含有自体骨的缺陷。操作后八周,使用组织学和组织形态学评估材料的效率。此外,使用常规血液检查,血液化学检查和内脏组织病理学检查评估材料的安全性。 BMP2 Incorporatedβ-TCP证明了与自体骨骼相当的骨再生效率,具有最高水平的新骨形成(38.3±8.4mm〜3与30.1±9.9 mm〜3,P <0.05)。这四组血液中的所有临床实验指标都在正常范围内。此外,在内脏的组织病理学检查中没有任何与治疗有关的变化。本研究结果证明BMP2掺入的β-TCP可能是用于骨再生的自体骨的有望替代品。具有大型动物模型的未来临床试验和临床前试验是探讨BMP2掺入β-TCP的安全性和功效的必要条件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号